Takeda Pharmaceutical Company Limited
TAKHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 30, 2026
Scan Results
Daily timeframeTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. At a $50.43B market cap, Takeda Pharmaceutical Company Limited ranks as a large-cap company within healthcare. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.
Market Cap
$50.43B
Beta
0.10
P/E (TTM)
42.00
P/E (Fwd)
30.11
EPS (TTM)
$0.38
EPS (Fwd)
$0.53
ROE
2.6%
ROA
2.6%
Cash
$595.05B
Total Debt
$5.45T
Free CF
$356.63B
52W Change
5.8%
Annual Financials
Cash vs Debt
The company holds $595.05B in cash, though total debt stands at $5.45T. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $356.63B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 2.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.57T (2022) to $4.58T (2025), reflecting a 28% increase over the period.
TAK's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Takeda Pharmaceutical Company Limited carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Takeda Pharmaceutical Company Limited's trajectory.